Impact News +++ Ad-hoc News: CEOTRONICS AG (EQS) +++ CEOTRONICS Aktie +3,90%

HBM HOLDINGS Aktie

>HBM HOLDINGS Aktienkurs

1.405 EUR (Tradegate)

Ask: 1.44 EUR / 1386 Stück

Bid: 1.37 EUR / 1462 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

HBM HOLDINGS Aktie über LYNX handeln

Intraday

1 Jahr

>HBM HOLDINGS Performance

1 Woche: -2,7%

1 Monat: -6,6%

3 Monate: -18,9%

6 Monate: +40,9%

1 Jahr: +914,3%

laufendes Jahr: +539,6%

>HBM HOLDINGS Aktie

Name:

HBM HOLDINGS LTD.

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG4403H1002 / A2QJVC

Symbol/ Ticker:

6XY (Frankfurt)

Kürzel:

FRA:6XY, ETR:6XY, 6XY:GR

Index:

Webseite:

https://www.harbourbiomed..

Profil:

HBM Holdings Ltd. is a publicly traded investment ..
>Volltext..

Marktkapitalisierung:

1290.86 Mio. EUR

Unternehmenswert:

1073.95 Mio. EUR

Umsatz:

97.8 Mio. EUR

EBITDA:

56.57 Mio. EUR

Nettogewinn:

61.77 Mio. EUR

Gewinn je Aktie:

0.08 EUR

Schulden:

55.07 Mio. EUR

Liquide Mittel:

273.54 Mio. EUR

Operativer Cashflow:

46.77 Mio. EUR

Bargeldquote:

5.56

Umsatzwachstum:

44.44%

Gewinnwachstum:

209.24%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

HBM HOLDINGS, HBM HLDGS, HARBOUR BIOMED

Letzte Datenerhebung:

17.12.25

>HBM HOLDINGS Kennzahlen

Aktien/ Unternehmen:

Aktien: 840.82 Mio. St.

Frei handelbar: 66.53%

Leerverk. Aktien: -

Rückkaufquote: -5.68%

Mitarbeiter: 183

Umsatz/Mitarb.: 0.18 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -

Bewertung:

KGV: 19.1

KGV lG: 19.56

KUV: 12.14

KBV: 4.96

PEG-Ratio: 0.08

EV/EBITDA: 18.99

Rentabilität:

Bruttomarge: 91.16%

Gewinnmarge: 63.15%

Operative Marge: 55.97%

Managementeffizenz:

Gesamtkaprendite: 24.22%

Eigenkaprendite: 35.8%

>HBM HOLDINGS Peer Group

Es sind 101 Aktien bekannt.

>HBM HOLDINGS Chart & Kurs - Tradegate

>HBM HOLDINGS News

17.12.25 - 03:00	HBM HOLDINGS-B Enters Strategic Co-op with Bristol Myers Squibb, May Receive Max. US$1.035B in Milestone Payments/ Royalties (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

17.12.25 - 02:54	Harbour BioMed, Bristol Myers More Than $1.1 Bln Deal For Next-Gen Multi-Specific Antibodies (AFX)
	NEW YORK CITY (dpa-AFX) - Harbour BioMed (2142.HK) announced that it has entered into a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb. The partnership ......

17.12.25 - 01:06	Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies (PR Newswire)
	SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global......

24.11.25 - 01:06	Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today......

07.11.25 - 07:01	Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a......

28.10.25 - 15:09	Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the launch of its first......

23.10.25 - 02:03	Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced positive Phase II......

29.08.25 - 03:45	HBM HOLDINGS-B Plans to Raise $512M by Placing Shrs at 9.5% Discount (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

27.08.25 - 16:42	Harbour BioMed Reports 2025 Interim Results (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today......

25.08.25 - 03:03	Harbour BioMed Appoints Yajie Li as Chief Medical Officer (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the......

30.07.25 - 02:03	Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025 (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present......

28.07.25 - 02:13	Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a......

23.06.25 - 02:06	Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic......

16.06.25 - 14:36	China National Intellectual Property Administration Affirms Validity of Harbour BioMed′s Patent; Infringement Lawsuit Moves Forward (PR Newswire)
	CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key......

01.05.25 - 20:51	MLC BREAKS GROUND ON NEW OPERATION IN BONNE TERRE, MO FOR DOLOMITIC LIME (PR Newswire)
	ST. LOUIS, May 1, 2025 /PRNewswire/ -- Leaders from MLC and its parent company, HBM Holdings, broke ground on a historic investment at MLC's Bonne Terre, Mo. location for dolomitic lime. MLC is completely refurbishing the site, a project that will be crowned with the commissioning of a......

10.04.25 - 04:03	Harbour BioMed Appoints Youchen Chen as Chief Financial Officer (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , April 9, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced the......

31.03.25 - 12:15	Harbour BioMed Reports Full Year 2024 Financial Results (PR Newswire)
	CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today......

21.03.25 - 13:07	Harbour BioMed Enters Strategic Collaboration With AstraZeneca (AFX)
	LONDON (dpa-AFX) - Harbour BioMed announced a global strategic collaboration with AstraZeneca to discover and develop multi-specific antibodies for immunology, oncology and beyond. Also, AstraZene......

21.03.25 - 12:42

AZN invests $2.5bn in Beijing R&D & manufacturing (Cision)

21 March 2025 AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai AstraZeneca today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance life sciences in China. This investment over...

21.03.25 - 12:24	Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies (PR Newswire)
	SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram